Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · April 07, 2016

Sulindac and Erlotinib for Duodenal Neoplasia in Familial Adenomatous Polyposis

JAMA: The Journal of the American Medical Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial
JAMA 2016 Mar 22;315(12)1266-1275, NJ Samadder, DW Neklason, KM Boucher, KR Byrne, P Kanth, W Samowitz, D Jones, SV Tavtigian, MW Done, T Berry, K Jasperson, L Pappas, L Smith, D Sample, R Davis, MK Topham, P Lynch, E Strait, W McKinnon, RW Burt, SK Kuwada

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading